---
title: "Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Drug interactions questions"
description: "Drug interactions questions on Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Verzenio interact with tamoxifen or aromatase inhibitors? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/drug-interactions"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer: Drug interactions questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Verzenio](https://uspl.lilly.com/verzenio/verzenio.html#pi)

Drug interactions questions that apply to every indication of Verzenio are on [Verzenio (abemaciclib), all indications: Drug interactions](https://www.evicenter.com/medical-information/verzenio/drug-interactions).

## Drug interactions

<a id="verzenio-endocrine-therapy-interactions"></a>

### Does Verzenio interact with tamoxifen or aromatase inhibitors?

> “Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of fulvestrant, imlunestrant, anastrozole, letrozole, exemestane, or tamoxifen on abemaciclib pharmacokinetics.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=Endocrine%20Therapies%3A%20In%20clinical%20studies,or%20tamoxifen%20on%20abemaciclib%20pharmacokinetics.)

> “Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of abemaciclib on the pharmacokinetics of fulvestrant, imlunestrant, anastrozole, letrozole, exemestane, or tamoxifen.”

Source: [VERZENIO: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/verzenio/verzenio.html#pi:~:text=serum%20cystatin%20C.-,Endocrine%20Therapies%3A%20In%20clinical%20studies%20in%20patients%20with%20breast%20cancer%2C,anastrozole%2C%20letrozole%2C%20exemestane%2C%20or%20tamoxifen.)

## Related pages
- [Medical information: Verzenio (abemaciclib): HR-positive HER2-negative early breast cancer](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/verzenio--hr-positive-her2-negative-early-breast-cancer/guidelines)
